Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

BACKGROUND: Ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unknown, which patients may benefit from relapse surgery. The aim of our study was to compare disease free sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Safi, S. A., Lehwald-Tywuschik, N., Rehders, A., Fluegen, G., Haeberle, L., Keitel, V., Knoefel, W. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931536/
https://www.ncbi.nlm.nih.gov/pubmed/33658016
http://dx.doi.org/10.1186/s12893-021-01082-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931536/
https://www.ncbi.nlm.nih.gov/pubmed/33658016
http://dx.doi.org/10.1186/s12893-021-01082-w

Ejemplares similares